Evaluation of the Polysaccharide “Immeran” Activity in <i>Syrian hamsters’</i> Model of SARS-CoV-2
Liubov Viktorovna Generalova,
Denis Pavlovich Laryushkin,
Irina Anatolievna Leneva,
Anna Valerievna Ivanina,
Galina Vladimirovna Trunova,
Sergei Vladimirovich Dolinnyi,
Evgenii Aleksandrovich Generalov
Affiliations
Liubov Viktorovna Generalova
Faculty of Medicine, Peoples’ Friendship University of Russia (RUDN University), 117198 Moscow, Russia
Denis Pavlovich Laryushkin
Federal Research Center “Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences”, Institute of Cell Biophysics of the Russian Academy of Sciences, 142290 Pushchino, Russia
Irina Anatolievna Leneva
Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia
Anna Valerievna Ivanina
Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia
Galina Vladimirovna Trunova
Federal State Budgetary Institution National Medical Research Radiological Center (FSBI NMRRC) of the Ministry of Health of the Russian Federation, P.A. Hertsen Moscow, Oncology Research Institute, 125284 Moscow, Russia
Sergei Vladimirovich Dolinnyi
Faculty of Medicine, Peoples’ Friendship University of Russia (RUDN University), 117198 Moscow, Russia
Evgenii Aleksandrovich Generalov
Faculty of Physics, Lomonosov Moscow State University, 119991 Moscow, Russia
COVID-19 is a highly contagious respiratory disease with a high number of lethal cases in humans, which causes the need to search for new therapeutic agents. Polysaccharides could be one of the prospective types of molecules with a large variety of biological activities, especially antiviral. The aim of this work was to study the specific antiviral activity of the drug “Immeran” on a model of a new coronavirus infection SARS-CoV-2 in hamsters. Based on the second experiment, intraperitoneal treatment with the drug according to a treatment regimen in doses of 500 and 1000 μg/kg (administration after an hour, then once a day every other day, a total of 3 administrations) was effective, reliably suppressing the replication of the virus in the lungs and, at a dose of 1000 μg/kg, prevented weight loss in animals. In all cases, the treatment stimulated the formation of virus-neutralizing antibodies to the SARS-CoV-2 virus, which suggests that the drug possesses adjuvant properties.
